Back to top
more

Arbutus Biopharma (ABUS)

(Delayed Data from NSDQ)

$3.34 USD

3.34
511,874

+0.07 (2.14%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $3.34 0.00 (0.00%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of -44.44% and 10.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 17.95% and 222.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Zacks Equity Research

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Zacks Equity Research

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

by Zacks Equity Research

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 12.50% and 17.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -56.10% and 21.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Emergent Biosolutions (EBS) Q4 Earnings Top Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 114.29% and 22.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 11.76% and 12.33%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

by Zacks Equity Research

Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 22.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?

by Zacks Equity Research

Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Zacks Equity Research

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Arbutus Biopharma (ABUS) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.

Zacks Equity Research

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arbutus Biopharma (ABUS) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of -10% and 12.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?

by Zacks Equity Research

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 28.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

by Zacks Equity Research

Here is how Arbutus Biopharma (ABUS) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 54.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up

by Zacks Equity Research

Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 16.67% and 7.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?